WuXi Biologics (Cayman) revenue and financials

2269 · HKEX · HKD

$56.70−2.07%−$1.20

Close · October 7, 2026

In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.

Annual revenue · 2025: ¥21.79B
  1. ¥10.29B2021
  2. ¥15.27B2022
  3. ¥17.03B2023
  4. ¥18.68B2024
  5. ¥21.79B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+16.68%
2025 vs 2024
Net income growth
+46.25%
2025 vs 2024
Net margin
22.5%
2024: 18.0%

Financial data

Amounts in millions of CNY; per-share values in CNY; shares in millions.

ItemQ2 2026Q4 2025Q2 2025Q4 2024Q2 2024Q4 2023Q2 2023Q4 2022Q2 2022Q4 2021
Total assets65,36363,69760,43756,97756,10656,57652,14149,56447,47344,033
Current assets27,19728,13524,44723,57319,81721,19817,87818,47020,65719,530
Cash and equivalents8,9049,2148,4398,2799,1549,6707,3556,3958,1359,003
Short-term investments3,5215,5873,1581,9073403402483043361,148
Receivables8,5678,8967,8216,3746,8026,6755,8585,7756,0454,181
Inventory1,7581,3811,6551,5221,9631,7661,9652,2812,1441,687
Net property, plant and equipment31,56229,75430,17528,43530,77629,93928,99525,91621,84619,756
Goodwill2,5761,5301,5301,5301,5301,5301,5301,5301,5301,530
Other intangible assets504467441442475512544549564601
Long-term investments3,0313,2033,0072,4002,8082,9342,7602,7092,4312,203
Current liabilities8,1908,3088,4878,6216,8087,6368,1419,3198,9968,256
Accounts payable1,3671,0929697478758335731,221995618
Long-term debt4501691852011,2641,5711,6591,462532641
Total debt—3,1045,107———————
Total liabilities10,84210,65711,37211,50011,46512,55813,09713,35111,99311,326
Total equity (incl. minority)54,52153,03949,06545,47844,64144,01839,04436,21335,48132,706
Retained earnings25,68223,24220,67318,33416,47714,978—11,5789,6937,158
Minority interest6,4505,7914,1133,6583,9863,6861,3061,1661,019428